You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A single-cell RNA sequencing analysis suggests progression to multiple myeloma involves shifts in immune cell representation and activity in the microenvironment.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.
The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
Data from MMRF's Immune Atlas will be included in its recently launched CureCloud, a registry of clinical, genomic, and EHR data from multiple myeloma patients.
A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.
Following FDA approval last October, Adaptive has now secured Medicare coverage for its NGS-based minimal residual disease assay, ClonoSeq.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.